Biotech · Public company · Fort Lee, NJ, US

Nuvectis Pharma, Inc.

Ticker NVCT · SEC CIK 0001875558

Track this companyFree. Adds Nuvectis Pharma, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials43 recruiting or active

Pipeline programs6From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline6

LorlatinibPhase 1 · ALK PositiveClinicalTrials.gov · fetched Nov 12, 2026
NXP800Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
NXP900Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
NXP900Phase 1 · ALK PositiveClinicalTrials.gov · fetched Nov 12, 2026
NXP900Phase 1 · EGFR Mutation Positive Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
OsimertinibPhase 1 · EGFR Mutation Positive Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026

Study of NXP900 With Lorlatinib in ALK+ Lung CancerPHASE1 · RECRUITING · started Aug 17, 2026ClinicalTrials.gov NCT07784959 · fetched Nov 12, 2026
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung CancerPHASE1 · RECRUITING · started Dec 18, 2025ClinicalTrials.gov NCT07315113 · fetched Nov 12, 2026
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced CancersPHASE1 · ACTIVE_NOT_RECRUITING · started Oct 26, 2023ClinicalTrials.gov NCT05873686 · fetched Nov 12, 2026
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian CancerPHASE1 · TERMINATED · started Dec 31, 2021ClinicalTrials.gov NCT05226507 · fetched Nov 12, 2026